Fulgent posts Phase 2 data: FID-007 plus cetuximab shows 60% ORR in HNSCC

• Fulgent Genetics flagged interim Phase 2 data for FID-007 used with cetuximab in recurrent or metastatic head and neck cancer, with the full abstract already published ahead of an ASCO rapid oral presentation scheduled for June 1, 2026.
• The study showed meaningful tumor-shrinking activity in patients whose disease had progressed on prior PD-1-based immunotherapy, supporting further clinical development in a setting with limited options.
• Safety was described as generally manageable, with most treatment-related side effects mild to moderate, though serious blood-related events were reported and one treatment-related death occurred.
• Survival follow-up remains early, keeping the near-term focus on response durability and whether the regimen can sustain benefits as additional data mature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605211703BIZWIRE_USPR_____20260521_BW761872) on May 21, 2026, and is solely responsible for the information contained therein.